In this study, we assessed the promoter methylation of an six-gene panel (SFN, P16, hMLH1, HOXD13, PCDHGB7 and RASSF1a) in serum samples by using MethyLight, to investigate whether it could be used for diagnosis of breast cancer or not. This evidence concerns the gene SFN and breast carcinoma.